CDRH names Jacobson acting director

Article

Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane

Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane Henney announced Burlington’s departure in January (SCAN 2/3/99) and appointed Jacobson as his temporary successor last month. Henney continues to seek a permanent replacement for the position.

Jacobson arrived at the FDA’s Bureau of Radiological Health in 1975 as a research geneticist. She has held several scientific and management posts at the Bureau and the CDRH, including director of the Office of Science and Technology and deputy director for science at the CDRH. Jacobson has served as acting director at the CDRH once before, from December 1992 to February 1993.

Jacobson will begin her tenure as acting director on March 13, when Burlington leaves for a new post as head of regulatory affairs at Wyeth-Ayerst Pharmaceuticals in Philadelphia.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.